Answers are grounded in this paper and cite their sources.
Our data show that no single parameter, including nodule size, satisfactorily identifies a subset of patients to be electively investigated by FNAC. We concluded that A/T > or = 1 with at least two of US features (microcalcification, blurred margins, hypo-echoic pattern) is today the best compromise between missing cancers and cost-benefit.
No takes yet. Share an insight, caveat, or question.
Cappelli et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: